Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Approves Ustekinumab for Pediatric Ulcerative Colitis

5 September 2026 · By · Wire by Fusion42

Published

5 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at gastroendonews.com →

◆ Verified

Fusion42 · 5 September 2026 · Fusion42 review

The FDA has approved ustekinumab as a treatment for pediatric patients with ulcerative colitis, expanding therapeutic options for this patient group in the United States.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

This approval opens a clear market access path in pediatric ulcerative colitis treatment for medtech founders focused on biologics. You should start aligning clinical strategies and payer discussions to capture newly legitimised demand.

◆ Coverage

1 source · 5 Sep 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalpediatriculcerative-colitisbiotechmedtech